Kidney International Reports最新文献

{"title":"Corrigendum to “Acute Kidney Injury Duration and 20-Year Risks of CKD and Cardiovascular Disease” [Kidney International Reports Volume 9, Issue 4, April 2024, Pages 817-829]","authors":"Simon K. Jensen , Uffe Heide-Jørgensen , Henrik Gammelager , Henrik Birn , Christian F. Christiansen","doi":"10.1016/j.ekir.2025.07.024","DOIUrl":"10.1016/j.ekir.2025.07.024","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Page 3294"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive Framework for Kidney Function Assessment: Summary of the National Institute of Diabetes and Digestive and Kidney Diseases Reimagining Kidney Function Assessment Workshop","authors":"Petter Bjornstad ,&nbsp;Phoom Narongkiatikhun ,&nbsp;Thomas Benzing ,&nbsp;Dana Y. Fuhrman ,&nbsp;Lesley Inker ,&nbsp;Bryan Kestenbaum ,&nbsp;Jay Koyner ,&nbsp;Kevin Lemley ,&nbsp;Jesse Seegmiller ,&nbsp;Sushrut S. Waikar","doi":"10.1016/j.ekir.2025.06.040","DOIUrl":"10.1016/j.ekir.2025.06.040","url":null,"abstract":"<div><div>Current kidney function assessment primarily relies on estimation of glomerular filtration rate (GFR), which fails to capture the full spectrum of kidney functions and may limit accurate disease classification and targeted treatments. To propose innovative strategies to comprehensively assess kidney functions, aiming to improve our capacity to uncover pathophysiologic mechanisms and delineate novel disease subgroups, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) convened a workshop titled “Re-imagining Kidney Function Assessment.” This workshop brought together experts to discuss current limitations and potential advancements in kidney function evaluation. Key themes emerged, including the following: (i) the need for standardized protocols for measured GFR using exogenous filtration markers, (ii) the potential of kidney functional reserve (KFR) and stress tests to reveal subclinical kidney dysfunction, (iii) the importance of assessing tubular secretion alongside glomerular filtration, (iv) the value of glomerular permselectivity measurements in predicting disease progression; and (v) the promise of integrating molecular profiling with functional assessments for precision medicine in nephrology. The workshop highlighted the critical need for a more comprehensive approach to kidney function assessment. Integrating diverse kidney function measures into tailored, individual-level assessments could lead to more accurate disease classification, targeted interventions, ability to track response to therapies, and improved patient outcomes. Future research should focus on developing and validating these novel assessment strategies to advance precision medicine in nephrology.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 2919-2936"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale and Design of the International Prospective Study of CKD of Uncertain Etiology in Agricultural Communities","authors":"Jill F. Lebov ,&nbsp;Daniel R. Brooks ,&nbsp;Anna Aceituno ,&nbsp;Hildaura Acosta ,&nbsp;Juan Amador Velázquez ,&nbsp;Shuchi Anand ,&nbsp;Aurora Aragón ,&nbsp;Mariela Arias-Hidalgo ,&nbsp;Vivek Bhalla ,&nbsp;Karen Courville ,&nbsp;Jennifer Crowe ,&nbsp;Idalina Cubilla-Batista ,&nbsp;Lawrence S. Engel ,&nbsp;Nora Franceschini ,&nbsp;David J. Friedman ,&nbsp;Ramón Garcia-Trabanino ,&nbsp;Marvin González-Quiroz ,&nbsp;Balaji Gummidi ,&nbsp;Carolina Guzmán-Quilo ,&nbsp;Vivekanand Jha ,&nbsp;Sushrut S. Waikar","doi":"10.1016/j.ekir.2025.06.044","DOIUrl":"10.1016/j.ekir.2025.06.044","url":null,"abstract":"<div><h3>Introduction</h3><div>There has been an alarming increase in the incidence of a chronic kidney disease (CKD) of unknown etiology primarily affecting young individuals engaged in agricultural activities in Mesoamerica and South Asia. Despite extensive research over the past 2 decades, causes remain unclear. The disease is characterized by progressive loss of kidney function with the absence of heavy proteinuria and hematuria. The International Prospective Study of CKD of Unknown Etiology in Agricultural Communities (CURE study) aims to do the following: (i) identify factors associated with kidney function decline among individuals with or at risk for CKD of uncertain etiology (CKDu); (ii) better characterize the clinical phenotypes of individuals with CKDu and differentiate them from other forms of CKD; (iii) employ advanced laboratory and data analysis methods to conduct discovery science related to risk factors, biomarkers, and causal mechanisms; and (iv) establish a biorepository for future research.</div></div><div><h3>Methods</h3><div>The CURE study is a prospective cohort study of up to 3600 participants from 7 sites in Central America and India aged 18 to 45 years with estimated glomerular filtration rate (eGFR) ≥ 20 ml/min per 1.73 m², no evidence of diabetes, and no other known causes of CKD. Biological samples and questionnaire data are collected from participants during 4 visits at 8-month intervals.</div></div><div><h3>Results</h3><div>Blood, urine, and hair will be analyzed for kidney function biomarkers, trace elements, pesticides and other contaminants, untargeted metabolomics, and genetic assays. Environmental samples, collected from a subset of study participants, will be analyzed for trace elements, agrochemicals, and burning exposures.</div></div><div><h3>Conclusion</h3><div>This study will provide novel information about CKDu etiology and clinical phenotypes across distinct geographies.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3192-3201"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Satisfaction Following a Session With a Kidney Genetic Counselor","authors":"Meg M. Hager ,&nbsp;Quinn Stein ,&nbsp;Emily Hendricks ,&nbsp;Maggie Westemeyer ,&nbsp;Edye Conway ,&nbsp;Cassie Vance ,&nbsp;Darbey Raible ,&nbsp;Kelsey McQueen ,&nbsp;Tessa Pitman","doi":"10.1016/j.ekir.2025.06.007","DOIUrl":"10.1016/j.ekir.2025.06.007","url":null,"abstract":"<div><h3>Introduction</h3><div>Genetic counseling’s impact on patients with kidney disease is understudied, despite 20% of adults with kidney disease having a monogenic cause. We sought to understand whether laboratory genetic counselors (GCs) provided a positive patient experience and increased access to genetic expertise.</div></div><div><h3>Methods</h3><div>A 47-question survey was developed and sent to patients following a genetic information session provided by laboratory GCs employed by a genetic testing company, to review genetic results from the Renasight^TM test (a multigene hereditary kidney panel).</div></div><div><h3>Results</h3><div>Over 18 months, 316 responses were recorded. Overall, 92% of respondents (228/247) indicated that the genetic information session was valuable to them. Most respondents (60%, 145/244) felt they had actionable steps to take after the session, including: meeting with an extrarenal specialist for management related to the genetic diagnosis, family planning, seeing a local genetics provider, or sharing results with relatives. In addition, 78% of respondents (193/247) felt that they had sufficient information to make decisions about their health care following their session. Only 13% of patients (34/253) were aware of their access to a local GC if the genetic information session was unavailable.</div></div><div><h3>Conclusion</h3><div>This study examined patient satisfaction following a discussion with a laboratory GC to review genetic test results for hereditary kidney disorders. This study demonstrates that laboratory GCs provide patients with increased access to genetic counseling, valuable information that helps patients and their families navigate their clinical journeys, and act as a complementary resource to providers ordering kidney genetic testing.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3174-3180"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Pilot Study of Plasma Cell–Targeted Therapy With Bortezomib in Refractory IgA Nephropathy","authors":"Li Lin ,&nbsp;Hong Ren ,&nbsp;Xiao Li ,&nbsp;Jingyuan Xie ,&nbsp;Nan Chen","doi":"10.1016/j.ekir.2025.06.006","DOIUrl":"10.1016/j.ekir.2025.06.006","url":null,"abstract":"<div><h3>Introduction</h3><div>IgA nephropathy (IgAN) is a leading cause of kidney failure, characterized by galactose-deficient IgA1 (Gd-IgA1) deposition and immune complex formation. Aberrant trafficking of IgA+ plasma cells and autoantibody production (IgG or IgA) contribute to disease pathogenesis. Proteasome inhibitors such as bortezomib may modulate B or plasma cell activity and reduce pathogenic antibody production.</div></div><div><h3>Methods</h3><div>This open-label, prospective, uncontrolled trial evaluated bortezomib in adults with biopsy-confirmed IgAN, proteinuria &gt; 1.5 g/d, and estimated glomerular filtration rate (eGFR) ≥ 30 ml/min per 1.73 m² despite optimized care. Patients received 4 to 8 doses of i.v. bortezomib at 1.1 to 1.3 mg/m² per dose. The primary end point was achieving 24-hour proteinuria (24 h–UP) &lt; 300 mg/24 h at 12 months. Secondary end points included changes in eGFR and adverse event monitoring.</div></div><div><h3>Results</h3><div>Sixteen patients completed the study. Median time from diagnosis to treatment was 63 months (range: 10–192). Baseline proteinuria was 2.719 g/24 h (95% confidence interval [CI]: 2.169–3.408), and mean eGFR was 51.1 ml/min per 1.73 m² (95% CI: 41.3–60.8). At 12 months, proteinuria decreased by 44.67%, with 6.25% achieving complete remission and 43.75% achieving ≥ 50% reduction. Proteinuria reduction persisted at 24 months (mean: 1.411 g/24 h: 48.09% reduction). The annual eGFR slope was −4.275 ml/min per 1.73 m². No serious treatment-related adverse events were reported.</div></div><div><h3>Conclusion</h3><div>Short course bortezomib therapy led to sustained proteinuria reduction in patients with IgAN, with an acceptable safety profile. These results support further evaluation in larger, controlled trials.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3023-3031"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Acthar gel and Tacrolimus in DNA-JB9 Positive Fibrillary Glomerulopathy","authors":"James A. Tumlin ,&nbsp;Amber Podoll ,&nbsp;Nelson Kopyt ,&nbsp;Brad Rovin ,&nbsp;Richard Lafayette ,&nbsp;Andrew Bomback ,&nbsp;Richard Glassock ,&nbsp;Jeremy Whitson ,&nbsp;Adam Press ,&nbsp;Gerald B. Appel","doi":"10.1016/j.ekir.2025.06.042","DOIUrl":"10.1016/j.ekir.2025.06.042","url":null,"abstract":"<div><h3>Introduction</h3><div>Fibrillary glomerulopathy (FGN) is a rare glomerular disease characterized by the deposition of randomly arranged fibrils that results in proteinuria and end-stage renal disease (ESRD) in up to 50% of patients within 2 years. The FACT trial is a prospective, randomized, open-labeled study of patients with biopsy-proven, DNA-JB9 positive FGN comparing the safety and efficacy of repository corticotropin (ACTH) injection, Acthar gel alone or in combination with tacrolimus on proteinuria and change in estimated glomerular filtration rate (eGFR).</div></div><div><h3>Methods</h3><div>Patients (<em>N</em> = 34) were randomized to ACTH 80 units subcutaneous 2×/wk alone or in combination with tacrolimus (1.0 mg 2×/d) for 12 months. Changes in the mean urinary protein-to-creatinine ratio (UPCR) and eGFR were reported at 6 and 12 months and last follow-up.</div></div><div><h3>Results</h3><div>A total of 34 patients completing 1 year of therapy were analyzed. In the ACTH-alone group (19 patients), UPCR decreased from a mean of 6.21 ± 0.8 g/g at baseline to 2.92 ± 0.90 g/g (<em>P</em> &lt; 0.009) at 6 months and 1.76 ± 1.3 g/g (<em>P</em> &lt; 0.02) at month 12. In the combination group (15 patients), mean UPCR decreased significantly from 6.00 ± 1.4 g/g at baseline to 4.27 ± 1.1 g/g (<em>P</em> &lt; 0.01) and to 1.83 ± 0.90 g/g (<em>P</em> &lt; 0.0006) at 6 and 12 months, respectively. At 12 months, combination therapy induced complete or partial responses in 13.3% and 53.3% compared with 15.8% and 26.3% in the ACTH alone group, respectively.</div></div><div><h3>Conclusion</h3><div>Repository ACTH (Acthar gel) significantly reduced UPCR at 6 and 12 months. The addition of tacrolimus was not additive with ACTH in reducing proteinuria or stabilization of eGFR. Acthar gel is an effective antiproteinuric therapy for DNA-JB9 positive FGN.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3128-3137"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risks, Diagnostic Thresholds, and Outcomes of Pediatric CKD in Rural Africa","authors":"Michael Abel Alao ,&nbsp;Olayinka Rasheed Ibrahim ,&nbsp;Andrew M. South ,&nbsp;Adebowale D. Ademola ,&nbsp;Valerie Ann Luyckx ,&nbsp;Wasiu Adekunle Olowu","doi":"10.1016/j.ekir.2025.06.038","DOIUrl":"10.1016/j.ekir.2025.06.038","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3280-3283"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent Chronic Thrombo-Inflammation in Anti–Glomerular Basement Membrane Disease Despite Immune Complex Removal","authors":"Mélodie Douté ,&nbsp;Linnéa Tyrberg ,&nbsp;Younès Youssfi ,&nbsp;Ingeborg Bajema ,&nbsp;Johan Mölne ,&nbsp;Antonino Nicoletti ,&nbsp;Giuseppina Caligiuri ,&nbsp;Mårten Segelmark ,&nbsp;Marc Clement","doi":"10.1016/j.ekir.2025.06.014","DOIUrl":"10.1016/j.ekir.2025.06.014","url":null,"abstract":"<div><h3>Introduction</h3><div>Anti–glomerular basement membrane (anti-GBM) disease is a severe autoimmune disease characterized by autoantibody-mediated glomerular damage, leading to a rapid decline in kidney function and end-stage renal disease. The stimulation of megakaryopoiesis (Mkpoiesis) and platelet production, driven by kidney-derived hematopoietic growth factors (HGFs) such as thrombopoietin (TPO), exacerbates chronic thrombosis and inflammation. Activated platelets release bioactive molecules able to promote microvascular dysfunction, cell proliferation, and excessive extracellular matrix deposition in injured glomeruli. Understanding the molecular mechanisms driving persistent thrombo-inflammation during anti-GBM disease will enhance therapeutic improvements. The hypothesis of this study was that anti-GBM disease could stimulate the production of kidney-derived HGFs and proinflammatory mediators. In addition, immobilized anti-GBM antibodies in glomeruli could directly activate FcγRIIA expressing platelets, thereby promoting chronic platelet activation during anti-GBM disease.</div></div><div><h3>Methods</h3><div>In the GOOD-IDES-01 trial, patients received, in addition to standard care, imlifidase (the IgG-degrading enzyme, IdeS). In plasma samples collected from patients with anti-GBM disease, before and after imlifidase treatment, and from healthy blood donors (HBDs), we analyzed plasma HGFs, proinflammatory and platelet activation markers, and platelet-derived products.</div></div><div><h3>Results</h3><div>Anti-GBM disease significantly elevated plasma proinflammatory and platelet activation markers, and HGFs (TPO and stem cell factor [SCF]). Plasma TPO correlated with anti-GBM titers. Standard care and imlifidase treatment only reduced TPO levels and platelet counts. Platelet activation markers (CD62P and Tlt1) strongly correlated with platelet-derived products (PDGF, CCL5, PF4, and TGFβ) during the active phase of the disease, but remained elevated despite the treatment.</div></div><div><h3>Conclusion</h3><div>Circulating HGFs, proinflammatory cytokines, and platelet activation markers are important biomarkers of anti-GBM disease activity. Chronic platelet activation, persists independently of anti-GBM antibody integrity, highlighting the need for therapies targeting thrombo-inflammation.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3138-3149"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney Involvement in Erdheim-Chester Disease","authors":"Emanuele D’Arpino ,&nbsp;Francesco Pegoraro ,&nbsp;Augusto Vaglio ,&nbsp;Francesco Peyronel","doi":"10.1016/j.ekir.2025.06.020","DOIUrl":"10.1016/j.ekir.2025.06.020","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3288-3291"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Community-Acquired Acute Kidney Injury and Late Kidney Dysfunction in Survivors of COVID-19 Hospitalization","authors":"Heitor S. Ribeiro ,&nbsp;Marcella M. Frediani ,&nbsp;Lia Marçal ,&nbsp;Leila Antonângelo ,&nbsp;Guilherme S. Catharina ,&nbsp;Luis Yu ,&nbsp;Dirce M.T. Zanetta ,&nbsp;Thais Mauad ,&nbsp;Tiana C.L. Moreira ,&nbsp;Nelson Gouveia ,&nbsp;Geraldo F. Busatto ,&nbsp;Carlos R.R. Carvalho ,&nbsp;Emmanuel A. Burdmann ,&nbsp;HCFMUSP COVID-19 Study Group","doi":"10.1016/j.ekir.2025.06.048","DOIUrl":"10.1016/j.ekir.2025.06.048","url":null,"abstract":"<div><h3>Introduction</h3><div>Data on the incidence and risk factors for renal long COVID are scarce. We aimed to investigate 2 acute kidney injury (AKI) phenotypes, namely community-acquired (CA; CA-AKI) and hospital-acquired (HA; HA-AKI), and the development of late kidney dysfunction in survivors of COVID-19 hospitalization.</div></div><div><h3>Methods</h3><div>This is a prospective cohort study of survivors of moderate-to-severe COVID-19 hospitalization in Brazil, from March to August 2020. The patients were assessed for up to 11 months after hospital discharge. Exposure was CA-AKI and HA-AKI. The main outcome was kidney dysfunction defined as incident low estimated glomerular filtration rate (eGFR; &lt; 60 ml/min per 1.73 m²) and/or eGFR decline ≥ 25% from discharge at follow-up. An adjusted binary logistic regression analysis was run.</div></div><div><h3>Results</h3><div>A total of 655 survivors were evaluated (6.5 ± 1.9 follow-up months); 79% had AKI (35% CA and 43% HA); 14% used kidney replacement therapy (KRT). Late kidney dysfunction occurred in 28% of the patients (16% with incident low eGFR and 27% with eGFR decline ≥ 25%). CA-AKI, but not HA-AKI, was independently associated with late kidney dysfunction (adjusted odds ratio [aOR] = 7.3, 95% confidence interval (CI): 3.6–15.8 and aOR = 2.2, 95% CI: 0.9–4.8, respectively).</div></div><div><h3>Conclusion</h3><div>In conclusion, late kidney dysfunction affected 1 in 4 COVID-19 survivors. CA-AKI, but not HA-AKI, was an independent risk factor for late kidney dysfunction. These findings suggest that renal long COVID might be frequent and that a specific AKI phenotype (CA-AKI) may play a crucial role in its development. Our research highlights the need for CA-AKI prevention and for the long-term follow-up and care of patients affected by this AKI phenotype during COVID-19 infection.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3032-3043"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}